trial

Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

NCTId NCT01617200
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 105 (actual)
Sponsored by Forest Laboratories
Primary completion 2015-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
105 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
Double
Start
2012-12
Primary completion
2015-03
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
AsenapineOlanzapine

Sponsors

Forest LaboratoriesLead Sponsor

Sites

1 total
Austin, United States

Linked catalysts

1
Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who — primary completion2015-03

Facts & assertions

4 sourced
Enrollment
105
Phase
PHASE3
Primary Completion Date
2015-03
Status
COMPLETED
relationships
The graph out of here
drug
Asenapine
drug
Olanzapine
drug
lead_sponsor
Forest Laboratories
company
indication
Schizophrenia
indication
Schizophrenia
indication